The DOI matches its Crossref record.
The p53 functional circuit
Abstract
The p53 gene is a tumor suppressor gene that plays a critical role in safeguarding the integrity of the genome. p53 is mutated or part of its regulatory circuit is functionally inactivated in almost all cancers, which highlights its importance in preventing tumorigenesis. The p53 protein is a sequence-specific DNA-binding transcription factor that is kept at a low level in cells under normal circumstances. Various stress signals, such as DNA damage, can stabilize and activate p53. Upon activation, p53 binds to the enhancer/promoter elements of downstream target genes and regulates their transcription, through which it initiates cellular programs that account for most of its tumor-suppressor functions.The functional signal transduction circuit of p53 consists of the upstream mediators (which sense and relay stress signals to p53), the core regulation components (which form the core circuitry maintaining and regulating p53 levels) and the downstream effectors (which initiate cellular response programs).The core regulatory circuitry consists of p53, Mdm2, p14ARF (p19Arf in the mouse) and E2F-1. These are organized into two interactive feedback loops. p53 and Mdm2 form one feedback loop, in which p53 positively regulates Mdm2 by activating Mdm2 transcription, and Mdm2 negatively regulates p53 by promoting p53 ubiquitination and degradation. E2F-1 and p14ARF form a similar feedback loop, in which E2F-1 activates ARF transcription, and p14ARF facilitates proteolytic degradation of E2F-1. These two feedback loops are connected in two ways. First, p14ARF interacts with Mdm2, inhibiting Mdm2-mediated p53 ubiquitination and degradation, thereby stabilizing p53. Second, p53 represses transcription of the ARF gene. This complex circuit is essential for maintaining and regulating p53 intracellular levels and activities. Some aspects of this circuit are defective in all cancers. Missense mutations of p53, amplification of MDM2, silencing or deletion of ARF and/or the loss of E2F-1 regulation through RB mutation are the most common mechanisms by which tumor cells alter the circuitry.Cellular stresses signal to p53 by perturbing the p53 core regulatory circuitry directly or indirectly. Several stresses activate p53, including DNA damage, oncogene activation, hypoxia, cellular ribonucleotide depletion, mitotic spindle damage and nitric oxide (NO) production. DNA damage activates p53 through p53 upstream mediators, which include protein kinases, transcriptional coactivator complexes with histone (protein) acetyltransferase activity, transcriptional co-repressor complexes with histone (protein) deacetylase activity, and other p53 activity modulators, such as Sumo-1 ligases, PML complex, Werner’s Syndrome protein (WRN) and HMG-1 protein. Most of these upstream mediators target p53 for post-translational modification. For example, DNA damage activates the protein kinases ATM, ATR, CHK1 and CHK2, which in turn phosphorylate p53 and/or Mdm2. Phosphorylation of p53 and/or Mdm2 activates p53 through three mechanisms: (1) stabilizing p53 by disrupting p53-Mdm2 interaction; (2) regulating p53 transactivation activity; (3) promoting p53 nuclear localization. Activated p53 recruits transcriptional coactivator or co-repressor complexes to the enhancer/promoter regions of its downstream target genes, facilitating or repressing their transcription, respectively. These transcription cofactor complexes can either acetylate or deacetylate p53 itself, which increases or decreases p53 stability and its DNA-binding affinity, respectively. In addition, another post-translational modification, sumoylation, of p53 appears to modulate p53 levels and activity. In contrast, oncogenes usually regulate p53 by altering transcription and/or activity of the ARF gene. For example, the oncogenes E2F-1, Ras, DMP1 and Myc enhance ARF transcription, whereas Twist, Bmi-1 and TBX2 downregulate it. The mechanisms by which other stresses activate p53 are not fully understood.Upon activation, p53 in turn activates or represses the transcription of its downstream effector genes, through which it may trigger several cellular programs, including cell cycle arrest, apoptosis, inhibition of angiogenesis/metastasis, and DNA repair. p53 may induce G1-S arrest by activating p21, a CDK2 inhibitor, or it may trigger G2-M arrest by inducing 14-3-3δ, GADD45, Reprimo and b99, which leads to CDC2 inhibition. p53 induces apoptosis by activating many pro-apoptosis genes, which ultimately activate Apaf-1 and caspase 9 through several pathways. p53 can activate anti-angiogenesis genes such as TSP1, BAI-1, MASPIN, GD-AiF and anti-metastasis genes such as KAI. p53 can also activate genes involved in DNA repair, including p48 in the nucleotide excision repair (NER) pathway and non-S-phase ribonucleotide reductase (R2). Finally, p53 can activate or repress genes that have undefined functions. Among these are those that encode cyclin G, EF-Iα, Wip1 and Map4. Different types of cellular s
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The p53 pathway: positive and negative feedback loops
Harris, S. L., & Levine, A. J. (2005) · Oncogene · doi:10.1038/sj.onc.1208615 · Cited by 1,967
Self-citationBond, G. L., Hu, W., Bond, E. E., Robins, H., Lutzker, S. G., Arva, N. C., Bargonetti, J., Bartel, F., Taubert, H., Wuerl, P., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.022 · Cited by 1,265
Self-citationThe coordinate regulation of the p53 and mTOR pathways in cells
Feng, Z., Zhang, H., Levine, A. J., & Jin, S. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502857102 · Cited by 1,235
Self-citationBeyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis
Cully, M., You, H., Levine, A. J., & Mak, T. W. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1819 · Cited by 1,233
Self-citationHaupt, S., Berger, M., Goldberg, Z., & Haupt, Y. (2003) · Journal of Cell Science · doi:10.1242/jcs.00739 · Cited by 1,136
The ubiquitin ligase COP1 is a critical negative regulator of p53
Dornan, D., Wertz, I., Shimizu, H., Arnott, D., Frantz, G. D., Dowd, P., O' Rourke, K., Koeppen, H., & Dixit, V. M. (2004) · Nature · doi:10.1038/nature02514 · Cited by 704
The Regulation of Exosome Secretion: a Novel Function of the p53 Protein
Yu, X., Harris, S. L., & Levine, A. J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4579 · Cited by 688
Self-citationCancer as a robust system: implications for anticancer therapy
Kitano, H. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1300 · Cited by 456
TP53 Mutations in Nonsmall Cell Lung Cancer
Mogi, A., & Kuwano, H. (2011) · BioMed Research International · doi:10.1155/2011/583929 · Cited by 388
Han, M.-K., Song, E.-K., Guo, Y., Ou, X., Mantel, C., & Broxmeyer, H. E. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2008.01.002 · Cited by 368
CAJAL BODIES: A Long History of Discovery
Cioce, M., & Lamond, A. I. (2005) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.20.010403.103738 · Cited by 358
A plausible model for the digital response of p53 to DNA damage
Ma, L., Wagner, J., Rice, J. J., Hu, W., Levine, A. J., & Stolovitzky, G. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501352102 · Cited by 356
Self-citationCoordination and communication between the p53 and IGF-1–AKT–TOR signal transduction pathways
Levine, A. J., Feng, Z., Mak, T. W., You, H., & Jin, S. (2006) · Genes & Development · doi:10.1101/gad.1363206 · Cited by 321
Self-citationThe First Approved Gene Therapy Product for Cancer Ad- p53 (Gendicine): 12 Years in the Clinic
Zhang, W.-W., Li, L., Li, D., Liu, J., Li, X., Li, W., Xu, X., Zhang, M. J., Chandler, L. A., Lin, H., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.218 · Cited by 318
MDM2 is a Central Node in the p53 Pathway: 12 Years and Counting
Bond, G., Hu, W., & Levine, A. (2005) · Current Cancer Drug Targets · doi:10.2174/1568009053332627 · Cited by 308
Self-citationThe p53MH algorithm and its application in detecting p53-responsive genes
Hoh, J., Jin, S., Parrado, T., Edington, J., Levine, A. J., & Ott, J. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.132268899 · Cited by 295
Self-citationOrth, J. D., Loewer, A., Lahav, G., & Mitchison, T. J. (2012) · Molecular Biology of the Cell · doi:10.1091/mbc.e11-09-0781 · Cited by 253
Toward a Molecular Classification of Melanoma
Fecher, L. A., Cummings, S. D., Keefe, M. J., & Alani, R. M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.0442 · Cited by 252
Overholtzer, M., Rao, P. H., Favis, R., Lu, X.-Y., Elowitz, M. B., Barany, F., Ladanyi, M., Gorlick, R., & Levine, A. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1934852100 · Cited by 193
Self-citationZaky, A., Busso, C., Izumi, T., Chattopadhyay, R., Bassiouny, A., Mitra, S., & Bhakat, K. K. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkm1173 · Cited by 111
Liu, G., & Chen, X. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.4.1398-1413.2006 · Cited by 104
Rochette, P. J., & Brash, D. E. (2008) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2007.12.007 · Cited by 68
Comparing Pearson, Spearman and Hoeffding’s D measure for gene expression association analysis
FUJITA, A., SATO, J. R., DEMASI, M. A. A., SOGAYAR, M. C., FERREIRA, C. E., & MIYANO, S. (2009) · Journal of Bioinformatics and Computational Biology · doi:10.1142/s0219720009004230 · Cited by 64
miR-23a binds to p53 and enhances its association with miR-128 promoter
Li, J., Aung, L. H. H., Long, B., Qin, D., An, S., & Li, P. (2015) · Scientific Reports · doi:10.1038/srep16422 · Cited by 45
Mallet, J. D., Dorr, M. M., Drigeard Desgarnier, M.-C., Bastien, N., Gendron, S. P., & Rochette, P. J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0162212 · Cited by 40
Pérez-Ramírez, C., Cañadas-Garre, M., Alnatsha, A., Villar, E., Delgado, J. R., Faus-Dáder, M. J., & Calleja-Hernández, M. Ÿ. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.08.002 · Cited by 33
PDCD4 Knockdown Induces Senescence in Hepatoma Cells by Up-Regulating the p21 Expression
Guo, J., Ozaki, I., Xia, J., Kuwashiro, T., Kojima, M., Takahashi, H., Ashida, K., Anzai, K., & Matsuhashi, S. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2018.00661 · Cited by 29
Metadata
- Authors
- Jin, S., & Levine, A. J.
- Venue
- Journal of Cell Science
- Publisher
- The Company of Biologists
- Published
- 2001-12-01
- Volume
- 114
- Issue
- 23
- Pages
- 4139-4140
- ISSN
- 0021-9533 (ISSN-L)
- 1477-9137
- OpenAlex
- W1920846434
- Cited by
- 307
- References
- 0
- FWCI
- 2.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.